← Stock Trading Canary · All insider profiles
INSIDER PROFILE · UK
Mazen Darwazah
Executive Vice Chairman
Profile key: uk|mazen darwazah
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 5
- Average purchase
- £2,055,504
- Gross purchase value
- £10,277,520
- Last purchase
- 2025-12-19
- Completed 20D events
- 4.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: Hikma Pharmaceuticals PLC
Companies: Hikma Pharmaceuticals PLC
Post-purchase outcomes
Benchmark-relative outcomes are available against FTSE 100.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small sample | 100.0% (4/4) | 50.0% (2/4) | +0.8% | +0.7% | -1.3% |
| 20D | 4Small sample | 100.0% (4/4) | 50.0% (2/4) | -0.5% | +0.7% | -3.7% |
| 60D | 4Small sample | 100.0% (4/4) | 0.0% (0/4) | -7.5% | -9.1% | -19.1% |
| 120D | 4Small sample | 100.0% (4/4) | 0.0% (0/4) | -21.3% | -22.4% | -38.1% |
Research patterns
- First purchase in 12M
- 0/3
- Large purchase ≥ €100k
- 4/4
- Cluster buying · 15D
- 1/4
- Buying the dip · ≥20% below prior 52W high
- 4/4
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.